Business Context and Reporting Period
The supplied filing is a Form 10-Q for Zeta Acquisition Corp. III, not Kura Oncology, Inc. It covers the quarter ended March 31, 2014 and was filed May 15, 2014. Zeta describes itself as a development-stage blank-check and shell company formed to identify and complete a business combination. It had no operating business, revenue, or identified target during the period.
Financial Metrics
| Metric | Q1 2014 / March 31, 2014 | Comparable Period / December 31, 2013 |
|---|---|---|
| Revenue | $0; none since inception | $0; none since inception |
| Net loss | $5,766 | $5,973 in Q1 2013 |
| Operating loss | $4,138 | $4,716 in Q1 2013 |
| Interest expense | $1,628 | $1,257 in Q1 2013 |
| Cash and cash equivalents | $6,168 | $6,568 at December 31, 2013 |
| Total assets | $6,793 | $9,068 at December 31, 2013 |
| Current liabilities | $136,516 | $133,025 at December 31, 2013 |
| Stockholders' deficit | $129,723 | $123,957 at December 31, 2013 |
| Net cash used in operating activities | $400 | $1,901 in Q1 2013 |
| Debt | $110,000 of notes payable to stockholders | $110,000 |
No meaningful operating margin is presented because the company has no revenue. The company reported a basic and diluted loss of approximately $0.00 per share for the quarter, based on 5,000,000 weighted-average shares.
Material Changes Versus the Prior Comparable Period
- Net loss decreased by $207, or approximately 3%, from $5,973 in Q1 2013 to $5,766 in Q1 2014.
- Operating expenses decreased to $4,138 from $4,716, while interest expense increased to $1,628 from $1,257.
- Operating cash use improved to $400 from $1,901.
- Cash declined by $400 from December 31, 2013, while total liabilities increased by $3,491, primarily from accrued interest and accrued expenses.
- Accumulated deficit increased to $179,723 from $173,957 at year-end 2013.
Guidance, Outlook, Risks, and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and anticipated costs for SEC reporting and evaluating or consummating a business combination. No target had been identified, and management stated that it had not had discussions with representatives of other entities regarding a combination since the registration statement became effective.
The company reported substantial going-concern uncertainty. Its $6,168 of cash was materially below current liabilities of $136,516, and it depends on additional financing, stockholder advances, or equity financing associated with a potential reverse merger. Management provided no assurance that funding would be available or that a business combination would occur.
Stockholder notes are unsecured, bear 6% interest, and are payable on demand. Accrued and unpaid interest was $18,803 at March 31, 2014. The company had no material legal proceedings, no material off-balance-sheet arrangements, and no stated contractual obligations requiring disclosure. Office space and equipment were provided by an officer and director at no cost on a month-to-month basis.
Management concluded that disclosure controls and procedures were effective as of March 31, 2014, with no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Verify the issuer identity: the supplied filing names Zeta Acquisition Corp. III, while the request identifies Kura Oncology, Inc.
- Confirm that the filing is the intended March 31, 2014 Form 10-Q and that its financial statements relate to the desired company.
- Assess the going-concern disclosure, including cash of $6,168 versus current liabilities of $136,516.
- Review the terms, maturity, related-party status, and enforceability of the $110,000 stockholder notes and accrued interest.
- Determine whether any business combination, financing, or reverse-merger transaction occurred after the filing date.